NB-CITALOPRAM 10 MG
CITALOPRAM (CITALOPRAM HYDROBROMIDE) : 10 MG · DIN 02555999 · NB PHARMA INC.
Health Canada status: MARKETED
What is NB-CITALOPRAM?
NB-CITALOPRAM 10 MG contains CITALOPRAM (CITALOPRAM HYDROBROMIDE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02555999, held by NB PHARMA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 16-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NB-CITALOPRAM used for?
Symptomatic relief of depressive illness in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02555999 |
|---|---|
| Brand name | NB-CITALOPRAM |
| Generic / active ingredient | CITALOPRAM (CITALOPRAM HYDROBROMIDE) : 10 MG |
| Manufacturer | NB PHARMA INC. |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB04 CITALOPRAM |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Jul-2025 |
How is it administered?
Administer once daily (morning or evening) with or without food. Usual dose 20 mg/day; maximum 40 mg/day. Titrate at intervals of at least one week. Taper gradually when discontinuing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 was listed in TOC but text cut off).
How is it supplied?
10 mg: Bottles of 100. 20 mg & 40 mg: Blister packages of 30, bottles of 100 and 500.
Contraindications
Hypersensitivity to citalopram; concomitant use of MAOIs (or within 14 days of stopping); concomitant use of pimozide; patients with known QT interval prolongation or congenital long QT syndrome.
Warnings and precautions
Increased risk of self-harm and suicidal behavior. Risk of QT prolongation and Torsades de Pointes (do not exceed 40 mg/day). Risk of discontinuation symptoms if stopped abruptly.
Is CITALOPRAM in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 03 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AB04 CITALOPRAM. 55 of 149 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-CITALOPRAM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02374617 |
| AG-CITALOPRAM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02339390 |
| AG-CITALOPRAM | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02339404 |
| AG-CITALOPRAM TABLETS | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02513676 |
| AG-CITALOPRAM TABLETS | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02513684 |
| AG-CITALOPRAM TABLETS | 30 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02543060 |
| AG-CITALOPRAM TABLETS | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02513692 |
| APO-CITALOPRAM | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02246056 |
| APO-CITALOPRAM | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02246057 |
| AURO-CITALOPRAM | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02275562 |
Who else supplies CITALOPRAM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CITALOPRAM appears in 433 registered pack listings across 15 markets, published on 13 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.